Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Cell Division

Figure 2

From: Therapeutic targeting of cancer cell cycle using proteasome inhibitors

Figure 2

MAPK pathways and Proteasome inhibitors: Proteasome inhibitors modulate the members of MAPK pathway and control cell cycle of cancer cells. PIs inhibit the activation of ERK 1/2 protein, which is found to increase the expression of cyclin D1. PIs activate p38 MAPK which antagonizes the effect of ERK 1/2 and decrease cyclin D1. PIs also activate JNK which is known to inhibit the E2F activity.

Back to article page